Eli Lilly Acquires Scorpion Therapeutics’ Cancer Therapy for $2.5 Billion
Eli Lilly acquires Scorpion Therapeutics’ experimental cancer therapy, STX-478, for $2.5 billion. This oral PI3K inhibitor targets a key protein in cancer growth, offering a potential new treatment for breast cancer and advanced solid tumors.
Eli Lilly Acquires Scorpion Therapeutics’ Cancer Therapy for $2.5 Billion Read More »